GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: ABBV/GLPG-3221 | compound 19 [PMID: 31749908]
                                 
                                                         
                            Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: ABBV-3221(GLPG-3221) is a novel cystic fibrosis transmembrane conductance regulator (CFTR) corrector that is being developed in a collaboration between AbbVie and Galapagos for the treatment of cystic fibrosis [2]. It was designed to provide improved clinical efficacy when used in a triple combination with a CFTR potentiator and a second, but mechanistically distinct, corrector molecule. ABBV-3221 enhances channel activity by increasing pore opening whilst the channel's two nucleotide-binding domains are dimerized [1].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| In vitro (in cells with the homozygous F508delCFTR mutation from a CF donor), addition of ABBV-3221 (corrector 2; C2) to the combination of ABBV-2222 (corrector 1; C1, with a similar mechanism to lumacaftor) and GLPG1837 (potentiator) increased the CFTR current with an EC50 of 105 nM, and increased the maximum response by almost six-fold, compared to the double ABBV-2222/GLPG1837 combination [2]. | 
| Selectivity at ion channels | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
                                                                        
                                                                         
  | 
                                                                ||||||||||||||||||||||||||||||||||